Insmed Incorporated (NASDAQ:INSM) Receives $82.73 Average PT from Brokerages

Shares of Insmed Incorporated (NASDAQ:INSM) have been assigned a consensus rating of “Buy” from the sixteen ratings firms that are covering the stock, Marketbeat reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year is $82.73.

Several equities analysts have recently issued reports on INSM shares. Stifel Nicolaus upped their target price on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Thursday, August 29th. Truist Financial increased their price objective on Insmed from $85.00 to $100.00 and gave the company a “buy” rating in a report on Friday, October 11th. The Goldman Sachs Group increased their price objective on Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. increased their price objective on Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Thursday, October 3rd.

Insmed Stock Performance

Shares of Insmed stock opened at $70.96 on Thursday. The company has a market cap of $12.19 billion, a PE ratio of -13.17 and a beta of 1.11. Insmed has a 52 week low of $21.92 and a 52 week high of $80.53. The business has a 50 day moving average price of $73.83 and a 200-day moving average price of $60.03. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. The firm’s revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.78) earnings per share. Equities analysts anticipate that Insmed will post -5.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,882 shares of company stock worth $5,765,446. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. V Square Quantitative Management LLC purchased a new position in Insmed in the 3rd quarter worth approximately $30,000. EntryPoint Capital LLC bought a new stake in shares of Insmed in the first quarter worth about $33,000. Fidelis Capital Partners LLC bought a new stake in shares of Insmed in the first quarter worth about $34,000. GAMMA Investing LLC grew its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its stake in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 287 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.